IP Library Granted Patent US 11,931,382
Granted Patent B2
US 11,931,382 · App. 17/856,997 · Granted Mar 19, 2024

Generating CIK NKT cells from cord blood

Inventors: Rohit Duggal (San Diego, CA); Ranjeet Sinha (San Diego, CA)
Assignee: ImmunityBio, Inc.
A61K35/17A61K9/0019A61K39/395C12N5/0646C12N2501/2302C12N2501/2307C12N2501/2315C12N2501/26C12N2501/51C12N2501/515C12N2501/998
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,931,382
App. No.
17/856,997
Granted
Mar 19, 2024
Kind
B2
Abstract

Provided herein are methods and customized media compositions for culturing CIK NKT cells.

Claims (15)

1. A method of obtaining a population of CIK NKT cells, in which greater than 90% of the CIK NKT cells express CD56 and CD3 and less than 10% of the CIK NKT cells express Va24 from a blood sample, the method comprising: isolating mononuclear cells from the blood sample; and contacting the isolated mononuclear cells with i) IL-7, ii) ALT-803 or IL-15, iii) FLT3 ligand, and iv) Gal-Cer.

2. The method of claim 1 , wherein the IL-7 is present in a concentration ranging from 5 to 20 ng/mL.

3. The method of claim 1 , wherein the ALT-803, if present, is in a concentration ranging from 100 to 300 ng/mL.

4. The method of claim 1 , wherein the FLT3 ligand is present in a concentration ranging from 5 to 20 ng/mL.

5. The method of claim 1 , wherein the Gal-Cer is present in a concentration ranging from 2 to 10 μg/mL.

6. The method of claim 1 , wherein the method further comprises isolating the enriched CIK NKT cells from the rest of the blood sample.

7. The method of claim 6 , wherein the method further comprises expanding the isolated CIK NKT cells with an anti-CD3 antibody, anti-CD28 antibody, and IL2.

8. The method of claim 7 , wherein the Gal-Cer is present in a form of a Gal-Cer loaded CD1d tetramer.

9. The method of claim 7 , wherein the anti-CD3 antibody is present in an amount of 5 ng/mL to 60 ng/mL.

10. The method of claim 7 , wherein the anti-CD28 antibody is present in an amount of 0.111 g/mL to 2 μg/mL.

11. The method of claim 7 , wherein IL-2 is present in a concentration of 50 ng/mL to 500 ng/mL.

12. The method of claim 7 , wherein the obtaining of CIK NKT cells does not include interferon-gamma.

13. The method of claim 7 , wherein the population of expanded CIK NKT cells comprise cytotoxic effector cells that are cytotoxic in the absence of Gal-Cer.

14. The method of claim 7 , wherein greater than 90% of the population of expanded CIK NKT cells express CD56 and CD3, and less than 10% of the population express Va24.

15. A method of producing a population of CIK NKT cells from a blood sample, in which greater than 90% of the CIK NKT cells express CD56 and CD3 and less than 10% of the CIK NKT cells express Va24, the method comprising: 1) isolating mononuclear cells from the blood sample; and contacting the isolated mononuclear cells with IL-7, ALT-803 or IL-15, or FLT3 ligand, and Gal-Cer, thereby enriching the CIK NKT cells; 2) isolating the enriched CIK NKT cells from the rest of the blood sample; and 3) expanding the isolated CIK NKT cells with anti-CD3, anti-CD28, IL2, and Gal-Cer.

Assignments (3)
SECURITY INTEREST Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2022
From: DUGGAL, ROHIT; SINHA, RANJEET
To: NANTKWEST, INC.
Reel/Frame 060663/0528 →
CHANGE OF NAME Recorded Jul 28, 2022
From: NANTKWEST, INC.
To: IMMUNITYBIO, INC.
Reel/Frame 061003/0731 →
Continuity (3)
Continuation 17260544
Provisional Application 62696131 · Jul 10, 2018
Related Publication 20220347218A1 · Nov 3, 2022